An accurate, reliable, reproducible method for the detection of ALK rearrangement is essential for identifying NSCLC patients who are candidates for treatment with ALK inhibitor (crizotinib), a drug that has shown dramatic clinical response in a recent clinical trial [4]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.